Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Masuko

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Oncotarget|April 18, 2018
Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancerJose M Piulats, Jumpei Kondo, Hiroko Endo, et al.
Biochemical and Biophysical Research Communications|March 5, 2011
Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapyMayumi Ohkawa, Yoshiya Ohno, Kazue Masuko, et al.
Cancer Science|July 16, 2013
Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasiaTakeyuki Wada, Takatsugu Ishimoto, Ryo Seishima, et al.
Cancer Research|January 16, 2013
xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinomaMomoko Yoshikawa, Kenji Tsuchihashi, Takatsugu Ishimoto, et al.
Plos One|November 17, 2015
Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical RoleQinghua Yuan, Takako Furukawa, Takahiro Tashiro, et al.
Cancer Science|December 15, 2018
Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modesShiho Ueda, Hidemi Hayashi, Takako Miyamoto, et al.
International Journal of Molecular Sciences|May 28, 2022
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized <sup>64</sup>Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility StudyFukiko Hihara, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, et al.
Oncotarget|February 1, 2020
Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancersKouki Okita, Shogo Okazaki, Shinya Uejima, et al.
FEBS Open Bio|January 6, 2025
CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAbTakashi Nakano, Kouki Okita, Shogo Okazaki, et al.
American Journal of Respiratory Cell and Molecular Biology|March 22, 2019
Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary HypertensionSarasa Isobe, Masaharu Kataoka, Jin Endo, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Oncotarget|April 18, 2018
Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancerJose M Piulats, Jumpei Kondo, Hiroko Endo, et al.
Biochemical and Biophysical Research Communications|March 5, 2011
Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapyMayumi Ohkawa, Yoshiya Ohno, Kazue Masuko, et al.
Cancer Science|July 16, 2013
Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasiaTakeyuki Wada, Takatsugu Ishimoto, Ryo Seishima, et al.
Cancer Research|January 16, 2013
xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinomaMomoko Yoshikawa, Kenji Tsuchihashi, Takatsugu Ishimoto, et al.
Plos One|November 17, 2015
Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical RoleQinghua Yuan, Takako Furukawa, Takahiro Tashiro, et al.
Cancer Science|December 15, 2018
Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modesShiho Ueda, Hidemi Hayashi, Takako Miyamoto, et al.
International Journal of Molecular Sciences|May 28, 2022
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized <sup>64</sup>Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility StudyFukiko Hihara, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, et al.
Oncotarget|February 1, 2020
Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancersKouki Okita, Shogo Okazaki, Shinya Uejima, et al.
FEBS Open Bio|January 6, 2025
CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAbTakashi Nakano, Kouki Okita, Shogo Okazaki, et al.
American Journal of Respiratory Cell and Molecular Biology|March 22, 2019
Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary HypertensionSarasa Isobe, Masaharu Kataoka, Jin Endo, et al.
Pageof 9